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Abstract
Coronavirus infections, known as COVID-19, can induce a fatal respiratory system infection and also affect other organs, such as
the kidney and heart. The mortality rate has been estimated between 1 and 5% in previous reports; however, the mortality and
morbidity can be higher in patients with the immune-deficiency condition. Rheumatoid arthritis (RA) is one of the most
rheumatoid disorders, and it is important to report their clinical and paraclinical data when affected with COVID-19. Evidence
about their laboratory and radiologic findings is limited. In this case series, 10 cases of chronic and approved rheumatoid arthritis
(RA) affected by COVID-19 are presented. Only 40% had dry cough, but myalgia and weakness as the general first presentation
of infections was reported in most cases (80%). Gastrointestinal symptoms, including nausea/vomiting, diarrhea, anorexia, and
abdominal pain, were reported in 50% of individuals. In blood cell count, 30% of cases had thrombocytopenia, and ESR in all
cases was positive. Abnormal CRP and elevated LDHwere seen in 90% of cases. In HRCT assessment, all cases had an abnormal
parenchymal pattern, and 90% of cases presented the usual pattern of COVID-19 (bilateral multifocal GGO/consolidation).
Although it is a limited report, these findings are helpful for comparison of clinical and paraclinical cases in RA cases with normal
cases.
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Introduction
COVID-19, as a pandemic infectious disease, has caused great
fear and anxiety among the international communities in re-
cent months; however, the issue seems more critical when
reports suggest that the mortality in cases with underlying
diseases, such as diabetes, heart, and lung problems, as well
as consumers of immunosuppressive drugs, is higher [1].
There are few reports on clinical and paraclinical
characteristics of rheumatoid disorder cases affected by
COVID-19, which have a very limited population [2–4].
Firstly, it seems that cases with rheumatoid arthritis (RA), as
one of the most common rheumatologic disorder, are more
vulnerable to COVID-19, and morbidity is more expected
due to lung involvement as one of the prominent and impor-
tant involvements in such cases, but further studies refuted this
hypothesis [5, 6]. Iran is one of the largest centers of disease in
West Asia that, at the time of writing, more than 160,000
people have complained about the disease. In this work, as
the first from Iran, we report 10 cases of rheumatoid arthritis
whose COVID-19 has definitely been confirmed in laboratory
tests.
Case presentation
In this case series, 10 cases of chronic and approved rheuma-
toid arthritis (RA) affected by COVID-19 are presented.
Baqiyatallah Hospital is a university hospital in the capital
of Iran, Tehran, selected as a referral center for COVID-19
on the first days the disease announced. More than 10,000
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COVID-19 cases were diagnosed, managed, treated, and hos-
pitalized in this hospital.
The rheumatologic ward of the hospital as a referral center
for rheumatologic cases affected by COVID-19 was under
careful observation. RA cases referred to the hospital who
had the interest to take apart in the research project were se-
lected for more assessment, and their data were collected by a
methodological team.
The mentioned criteria were met by 13 cases, 3 of whom
had considerable missed data and thus were excluded. Ten
cases were included in the study; their clinical data and
paraclinical data (including radiologic and laboratory) were
presented as in Tables 1 and 2, respectively.
There are some considerable points in this group to be
noted:
Most cases had an age greater than 55 years old and were
female. Methotrexate and prednisolone were the most fre-
quent medication used. Four cases used hydroxychloroquine
as immune moderators (Table 3). Hydroxychloroquine was
used by 4 cases for relieving the COVID-19 symptoms and
preventing its progression; nevertheless, these cases showed
the radiologic and clinical features of COVID-19 (Table 2).
Only 4 cases had dry cough, but the most frequent
symptoms were fever and myalgia (7/10), dyspnea
(5/10), and GI symptoms, including anorexia (2/10), nau-
sea (3/10), and diarrhea (2/10). Myalgia and weakness as
the general first presentation of vital infections was re-
ported in most cases (8/10). Gastrointestinal symptoms,
including nausea/ vomiting, diarrhea, anorexia, and ab-
dominal pain, were reported in 5 cases, and the other 5
cases had predominant respiratory symptoms. Three cases
had no evidence of respiratory symptoms.
In blood cell count, 3 cases had thrombocytopenia, 2 cases
leucopenia, 2 cases anemia, 2 cases bicytopenia, and 1 case
pancytopenia. ESR, in all cases, was positive, and 9 cases had
abnormal CRP. Troponin, in one case, was abnormal, and
procalcitonin, in all cases, were normal. Only one case had
normal LDH (1/10), 6 cases had normal AST, and 3 cases had
normal ALT. CPK was abnormal in 3 cases. In HRCT assess-
ment, all cases had an abnormal parenchymal pattern, and 9
cases presented the usual pattern of COVID-19 (bilateral mul-
tifocal GGO/consolidation) (Fig. 1).
Discussion
In this case series, we reported 10 cases of RA with se-
rologically approved COVID-19. Almost all physical
symptoms and paraclinical features were similar to previ-
ous reports in RA cases and also normal healthy individ-
uals. It was approved that COVID-19 in immune-
suppressed cases, such as diabetic, rheumatologic cases,
and who are receiving immune suppressants such as cor-
ticosteroids is more severe [7, 8].
The reported range of incidence of positive PCR-confirmed
cases of COVID-19 is surprisingly wide, being reported be-
tween 57 per million in China and about 4000 per million in
Belgium [9]. Cultural and governmental disciplines have a
critical role in this variability. Similarly, the mortality rate of
COVID-19 is greatly wide; the highest mortality rates are
being reported by Italy as 13.1% and South Korea as 2.1%,
besides the lowest rates by Bahrain and Singapore as 0.3 and
0.4%, respectively [9]. As previously reported, higher age,
multi-organ dysfunction, and impaired laboratory markers,
Table 1 Demographic and clinical data
No/
sex
Comorbid. Age (duration) Cortico. (P) Others Cho/Hx Complaint, Ph.Exam Final
1 F DM, HTN 68 (7) 5(mg/d) MTX (20 mg/W)
Sul.(500 mg/D)
– Dry cough, myalgia, weakness Dis
2 F DM, HTN 58 (3) 0.6
(mg/d)
Sul. (500 m/BD) – Dry cough, dyspnea, chill and fever,
diarrhea, nausea
Dis
3 F – 56 (3) 5 (mg/D) MTX (10 mg/W) – Dry cough, fever, myalgia Dis
4 F – 58 (4) 5 (mg/D) MTX (10 mg/W) Hx (200 mg/D) Dyspnea, chill and fever, diaphoresis Dis
5 M HTN, CAD 67 (3) 5 (mg/D) MTX (7.5 mg/W)
Sul.(1 g/D)
Hx (200 mg/D) Weakness, nausea Dis
6 F – 47 (10) 2.5 (mg/D) MTX (10 mg/W) – Dry cough, dyspnea, chill and fever, myalgia Dis
7 F DM, HTN, CAD 80 (14) 5 (mg/d) Sul. (2 G/BD) – Dyspnea, chill and fever, myalgia, anorexia Dis
8 F – 59 (3) – AZA (50 mg/BD) Hx (200 mg/d) Myalgia, anorexia, diarrhea Dis
9 F CAD 57 (6) – AZA (50 mg/BD) – Dyspnea, fever, myalgia Dis
10 F HTN, CAD 67 (20) – – Hx (200 mg/d) Fever, myalgia, nausea, weakness Dis
F female, M male, Comorbid comorbidities, HTN hypertension, DM diabetes mellitus, Ph.Exam physical examination, Lab Data laboratory data, P
prednisolone, Sul. sulfasalasin, Cho chloroquine, Hx hydroxychloroquine, CRP C-reactive protein, ESR estimated sedimentation rate (ESR), B/M
bilateral/multifocal, GGO ground-glass opacities, Con. consolidation, Dis discharge with suitable condition, M milligram, BD twice daily
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such as D-dimer, have a significant role in higher mortality
rates [10]. Generally, it is declared that immune-suppressed
cases, such as corticosteroid receiving ones, are at higher risk
of a severe form of COVID-19; however, it is not completely
clear if patients with rheumatoid arthritis, who do not receive
immune suppressor, are also at risk or not [11]. Nevertheless,
what is clear is that cases with comorbidities, especially with a
history of lung disorders, have a higher risk of mortality [11].
In cases with rheumatologic diseases, some hypothetic risk
factors of mortality and morbidity, such as lung abnormalities,
received immune suppressor, higher age, and organ/
multiorgan damages, were potentially considered [12].
Table 2 Paraclinical data
Case No Lab data Radiologic findings
CBC Inflam.
CRP/ESR
Others (only remarkable) Trop/Procal Uni/bilateral
Multi/unifocal
Pattern Other
1 F NL. (Plt: 189) CRP: 21
ESR: 27
LDH; 918, AST: 142,
ALT: 217, CPK: 201
NL B/M Mixed GGO/Con Linear opacities





LDH; 577, AST: 29,
ALT: 56, CPK: 112
NL B/M GGO –
3 F NL (Plt: 160) CRP: 26
ESR: 41
LDH; 725, AST: 31,
ALT: 40, CPK: 295
NL B/M GGO –
4 F NL (Plt: 216) CRP: 11
ESR: 30
LDH; 538, AST: 27,
ALT: 86, CPK: 133





LDH; 693, AST: 1117,
ALT: 734, CPK: 192
NL B/M Mixed GGO/CP Linear opacities/reverse halo
6 F NL (Plt: 363) CRP: 5.5
ESR: 32
LDH; 632, AST: 24,
ALT: 49, CPK: 42
0.14/NL B/M Mixed GGO/Con –




LDH; 556, AST: 27,
ALT: 34, CPK: 19
NL B/M Consolidation Linear Opacities/reverse halo
8 F NL (Plt: 404) CRP: 10
ESR: 42
LDH; 587, AST:69,
ALT: 77, CPK: 50
NL B/M Consolidation Linear opacities/reverse halo
9 F NL (Plt: 327) CRP: 44
ESR: 50
NL NL B/M GGO –



















COVID-19 medication Duration of
hospitalization
1 F −/− Continue Meropenem/Kaletra/azythromycine 5
2 F −/− Continue/prednisolone increase
until 20 mg/d
Meropenem/HCQ 12
3 F −/− Continue Meropenem/levofloxacine/Kaletra/methylprednisolone/plasma
therapy
16
4 F −/− Continue Methylprednisolone/Kaletra 6
5 F +/+ Only MTX discontinued Methylprednisolone/azythromycine/HCQ/plasma
therapy/ASA/heparin
30
6 F −/− Continue Azythromycine/HCQ/prednisolone 10
7 F −/− Continue Levofloxacin/azythromycine/Kaletra/plasma therapy 1.5
8 F −/− Continue Azythromycine/Kaletra/ribavirin 11
9 F −/− Continue Meropenem/levofloxacin/Kaletra 6
10 F −/− Continue Tamiflu/HCQ/naproxen 5
Kaletra (lopinavir-ritonavir), HCQ hydroxychloroquine, ASA aspirin, MTX metotroxate
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However, mortality and morbidity in these cases were not
widely assessed, and contrary to initial reports warned about
higher mortality in immune-suppressed patients, recent publi-
cations confirmed that immune-suppressed cases had similar
or even less mortality rate versus normal population. These
can be since the host immune response, the main driver of
lung tissue damage, is impaired in immune-suppressed cases
[13, 14]. On the other hand, it is not clear that if immune-
suppressed cases, who previously had organ damage (e.g.,
renal injuries or lung parenchymal abnormalities), have a
Fig. 1 Multilobar bilateral GGo in two mentioned cases. a Case 5, b case 7
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higher rate of mortality/morbidity or not (versus cases with the
normal immune system).
Moreover, medications have a significant role in the out-
comes of cases with immune system dysfunction, such as
rheumatologic diseases. Monti et al., in a brief report about
13 cases of RA and spondyloarthritis, declared that none of
their cases progress to severe pulmonary complications, and
only one case was hospitalized. Although Monti et al., due to
the small size of the sample, described that “our findings do
not allow any conclusions on the incidence rate of SARS-
CoV-2 infection in patients with rheumatic diseases, nor on
the overall outcome of immunocompromised patients affected
by COVID-19” [4].
Monti et al. had 4 PCR confirmed cases, 4 clinically
suspected for COVID-19, and 5 with the positive past medical
history of positive case exposure, while we had 10 patients
with both PCR and radiological confirmation for COVID-19.
Similarly, fatigue, myalgia, dry cough, and fever were report-
ed in most cases.
In another report, Haberman et al. assessed patients with
known “immune-mediated inflammatory disease (RA, psori-
atic arthritis, ankylosing spondylitis, psoriasis, inflammatory
bowel disease, or related conditions) who were receiving anti-
cytokine biologics, other immunomodulatory therapies, or
both when confirmed or highly suspected symptomatic
COVID-19 developed.” They found that hospitalization in
RA cases, which was the most frequent disease in hospitalized
cases, commonly occurred in cases with comorbidities, such
as hypertension, diabetes, or chronic obstructive pulmonary
disease. They finally concluded that “an incidence of hospi-
talization among patients with the immune-mediated inflam-
matory disease was consistent with that among patients with
COVID-19 in the general population.” [15] In contrast, they
reported fever and cough as the most common symptoms;
they did not report myalgia and weakness in their cases.
Moreover, there was no data about the patient’s radiologic
features.
SLE, as another rheumatologic disease, was studied by
Sawalha et al. They aimed to assess epigenetic dysregu-
lation of ACE2 and interferon-regulated genes demethyl-
ation; they concluded that “lupus patients are more prone
to SARS-CoV-2 infections and complicated disease
course of COVID-19.” Finally, as a target, controlling
the ACE2 gene was recommended for the prevention
and therapy of COVID-19 [16].
Cheng et al. reported 5 cases of RA/systemic sclerosis
with COVID-19, and they described the clinical charac-
teristics. Cough and fever were the most common symp-
toms, and fatigue was reported in one case. Leukopenia
and lymphopenia in 2 patients were seen. In our report,
leucopenia was seen in 2 patients and lymphopenia in one
patient; however, thrombocytopenia was the most labora-
tory abnormality inconsistent with normal populations [2].
Although only 3 patients of them had increased CRP,
almost all cases had abnormal CRP and ESR in our re-
port. Some other inflammatory markers, such as IL 6/10,
were evaluated in the mentioned report, while we assessed
troponin and procalcitonin, finding it unuseful. Similarly,
all their cases in both studies had abnormal imaging find-
ings, most commonly GGo/consolidation opacities. Three
patients progressed to a more severe stage of COVID-19.
Regarding the pathogenic mechanisms of COVID-19
known so far, overactivation of the immune system may have
a critical role in the severe stage, and in rheumatologic cases,
due to native immune deficiency situation, the severe symp-
toms may be uncommonly presented [17, 18].
There are several laboratory biomarkers, which constantly
are suggested for diagnosis and prognosis of COVID-19, such
as interleukins (IL-6 and IL 10), ferritin, WBC count, platelet
count, together with LDH and liver function test. These labo-
ratory biomarkers also frequently are seen abnormal in this
report [19].
Radiologic features, in these reported cases, are also similar
to the normal population. In this and the previous reports on
normal cases, bilateral multifocal GGO is the most frequent
finding in lung HRCT of COVID-19 [12]; this finding is in
line with Ye et al.’s results of 4 cases of RA [20].They also
mention that respiratory failure is common in cases; this is not
seen in our case series with at least 2 times more sample size.
On the other hand, dose adjustment of immune suppressive
and immune-modulatory medications in rheumatologic cases
has been previously recommended; however, in our reports,
these cases are shown to have more unusual symptoms of
COVID-19 against the normal population in addition to un-
commonly progress to severe stage.
This theory is suggested based on the main pathology of the
severe immune response in critical cases of COVID-19, sug-
gesting that uncontrolled immune response such as cytokine
storm has a key role in the progressing stage of COVID-19
[21, 22]. Therefore, immune modulation is suggested for future
options in critically ill cases. DMARDS and other immune
cells’ regulatory medications, such as tocilizumab and cytokine
blood filtration, are presented as promising treatment options;
however, their efficacy in all cases is still unclear [21, 23].
Further evaluations on the role of immune regulatory med-
ications and innate immune systems in the activity and pro-
gression of the COVID-19 in rheumatologic disease cases are
recommended.
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